New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review
A comprehensive, up-to-date systematic review (SR) of the new-onset rheumatic immune-mediated inflammatory diseases (R-IMIDs) following COVID-19 vaccinations is lacking. Therefore, we investigated the demographics, management, and prognosis of new R-IMIDs in adults following SARS-CoV-2 vaccinations....
Main Authors: | Arvind Nune, Victor Durkowski, S. Sujitha Pillay, Bhupen Barman, Helen Elwell, Kaustubh Bora, Syed Bilgrami, Sajid Mahmood, Nasarulla Babajan, Srinivasan Venkatachalam, Lesley Ottewell, Ciro Manzo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-10-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/11/10/1571 |
Similar Items
-
CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases
by: Kevin Chevalier, et al.
Published: (2023-03-01) -
Frequency and course of COVID-19 in patients with rheumatic diseases (according to the data of V.A. Nasonova Research Institute of Rheumatology)
by: A. N. Kulikov, et al.
Published: (2023-10-01) -
SYMPTOMATIC THERAPY FOR PAIN IN RHEUMATIC DISEASES: A PLACE OF ACECLOFENAC
by: V A Nasonova, et al.
Published: (2009-09-01) -
Treatment strategy for fatigue in rheumatic diseases in view of the 2023 EULAR recommendations
by: E. S. Aronova, et al.
Published: (2024-06-01) -
Peripheral Neuropathy in Systemic Autoimmune Rheumatic Diseases—Diagnosis and Treatment
by: Jean Marcos De Souza, et al.
Published: (2023-04-01)